Introduction
============

Heterotopic ossification is the abnormal growth of bone in the non-skeletal tissues including muscle, tendons, or other soft tissue. Heterotopic ossification may occur in skeletal muscle wound, bone joint operation and the nervous system impairment ([@b1-etm-0-0-4327]). With the increase in the number of artificial joint replacement surgeries, the incidence rate of heterotopic ossification is increasing every year ([@b2-etm-0-0-4327]). Serious heterotopic ossification may result in arthrocele, pain, joint movement disorder and even loss of mobility. It may also cause neurological problems and pressure ulcers and seriously reduce patients\' life quality ([@b3-etm-0-0-4327]). The specific mechanism of heterotopic ossification is unclear, however there are several theories including ([@b4-etm-0-0-4327]): i) Trauma or orthopedic operation results in local bone tissue destruction, muscular death and haematoma formation; ii) paracrine and inflammation in injured tissues can release various cell factors, which allows local cell signal to change; iii) mesenchymal stem cells migrate toward injured position, and differentiate into cartilage cells and osteocyte; and iv) surrounding tissues provide a proper and stable internal environment for continuous growth of heterotopic bone tissue.

Wear particles may be related to osteolysis around prosthesis, which resulted in aseptic loosening of artificial joint and implantation failure ([@b5-etm-0-0-4327]). Wear particles may stimulate macrophages to produce interleukin-1 (IL-1), IL-6 and tumor necrosis factor-α (TNF-α), which play an important role in osteoclast occurrence, differentiation and maturity ([@b6-etm-0-0-4327]). Wear particles may also stimulate osteoblast around prosthesis to secrete core binding factor receptor activator of nuclear factor-κB ligand (RANKL) to reduce osteoprotegerin ([@b7-etm-0-0-4327]). Blocking wear particles stimulus response link and reducing ability of osteoclast production and activation had potential benefits to relieve or prevent bone around prosthesis dissolving.

After in-depth analysis on possible mechanism involved in aseptic loosening of artificial joint, we planned to introduce wear particles into the treatment process. We discussed the feasibility and possible mechanism by establishing animal model formed by high molecular polyethylene particles local intervention and inhibition on heterotopic ossification, which provided a new method to prevent heterotopic ossification.

Materials and methods
=====================

### Experimental animals

A total of 36 healthy Sprague-Dawley rats aged from 6 to 8 weeks with average weight of 180 g were used in this study. They were obtained from Shanghai Sangon Animal Experimental Center (Shanghai, China), and were fed normally for one week prior to the beginning of the experiment. Pentobarbital (30 mg/g) was injected into abdominal cavity for anesthesia, and posterolateral approach of right leg was used to transect at midpoint of Achilles tendon, clamp was used to clip at both ends of fractured Achilles tendon and no suture was used for Achilles tendon. X-ray and bone histomorphometry were used for to determine success of the operation.

### Research method

Rats were randomly divided into the control group (n=18) and the observation group (n=18), and high molecular polyethylene particles (1.0 wt %) were injected to rupture Achilles tendon position in the observation group, and normal saline was injected in the control group. Skin was sutured, and rats were fed routinely and observed. Antibiotic was used to prevent infection. X-ray examinations were conducted on Achilles tendon in the 4th, 8th and 12th week after operation. The incidence rate of heterotopic ossification was evaluated, and bone trabecula morphological structure was studied under optical microscope (BX-42; Olympus, Tokyo, Japan) after hematoxylin and eosin (H&E) staining. Bone morphogenetic protein 2 (BMP-2), transforming growth factor-β (TGF-β), IL-1, TNF-α, runt-related transcription factor 2 (Runx2) and matrix metalloproteinase-9 (MMP-9) expression levels were also measured.

### Preparation of high molecular polyethylene particles

The mean diameter of high molecular polyethylene particles was 3.6 µm (range, 0.8--23 µm), with irregular shape. Particles were dissolved in 75% ethyl alcohol, shaken and washed 4 times (one hour each time) at room temperature. Consequently, particles were soaked in 100% ethyl alcohol to eliminate endotoxin.

### X-ray examination

To study the formation of heterotopic bone, injured Achilles\'s tendons were examined with a Kodak X-ray machine (AA400; Kodak, Rochester, NY, USA).

### Visual observation and histological examination of Achilles tendon

Rats were sacrificed by quick neck removal method and samples from Achilles tendons were collected. The color, thickness, elasticity and flintiness of tendon was examined and heterotopic bone formation was verified. Samples were fixed with 10% neutral formalin for 24 h and decalcified for 1 week with 15% EDTA. Samples were then dehydrated using gradient ethanol and then embedded with transparent paraffin in order to prepare 5-µm sections. H&E straining was performed and bone trabecula structure was observed under Olympus optical microscope (BX-42; Olympus). This study was approved by the Animal Ethics Committee of Zhejiang University Animal Center.

### Immunohistochemical staining

Frozen sections were fixed in cold acetone for 15 min, and hatched in 3% hydrogen peroxide for 10 min at room temperature to eliminate endogenous peroxidase. Samples were washed 3 times (5 min each time) with phosphate-buffered saline (PBS) and primary antibody was then added. Primary antibodies including rabbit monoclonal BMP-2 antibody (dilution, 1:50; cat. no. SAB1306267), rabbit monoclonal TGF-β antibody (dilution, 1:50; cat. no. SAB4301267) rabbit polyclonal IL-1 antibody (dilution, 1:50; cat.no. SAB4503272) rabbit monoclonal TNF-α antibody (dilution, 1:50; cat. no. SAB2108244), rabbit monoclonal Runx2 antibody (dilution, 1:50; cat. no. SAB4301114) and rabbit polyclonal MMP-9 antibody (dilution, 1:50; cat. no. HPA001238) were from Sigma-Aldrich (St. Louis, MO, USA). For negative control we used PBS instead of primary antibody. Samples were soaked in 37°C electrothermal constant-temperature water tank and were washed with PBS three times (5 min each time). Secondary goat anti-rabbit (HRP) IgG antibody (dilution, 1:2,000; cat. no. ab6721) from Abcam (Cambridge, MA, USA) was then added and samples were incubated for 30 min at room temperature. Samples were the verified under optical microscope, followed by flushing, re-staining, dehydration and mounting. When faint yellow color was observed in the cytoplasm or endochylema, sample was marked as positive. We selected 5 high-power field (x400) randomly, and made the overall rating by straining intensity combined with positive cell percentage.

### Statistical analysis

SPSS 20.0 statistical software (IBM, Armonk, NY, USA) was used for statistical analysis. Gaussian distribution data are presented as mean ± standard deviation. For comparison t-test or variance analysis by repeatedly measuring data were used. Qualitative data are presented as rate, and for comparison χ^2^ test was used. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Heterotopic ossification incidence comparison

Four weeks after operation, there were 8 rats with heterotopic ossification in the control group and 2 in the observation group. Eight weeks after operation, there were 14 rats with heterotopic ossification in the control group and 5 in the observation group. Twelve weeks after operation, there were 18 rats with heterotopic ossification in the control group and 9 in the observation group. Heterotopic ossification incidence in the observation group was significantly lower than that in the control group and the difference had statistical significance (P\<0.05). The incidence increased in both groups with time ([Fig. 1](#f1-etm-0-0-4327){ref-type="fig"}).

### Visual inspection and histological examination

Achilles tendon structure in the control group increased in volume, and its texture was harder and cartilage-like. With H&E staining, cartilage cells and granulation tissue proliferation were observed. In the observation group, trabecular bone volume, thickness and quantity were more than those observed in the control group and the difference had statistical significance (P\<0.05) ([Table I](#tI-etm-0-0-4327){ref-type="table"}).

### Inflammatory factors

BMP-2, TGF-β, IL-1, TNF-α, Runx2 and MMP-9 levels in observation group were significantly lower than those in the control group, and the difference had statistical significance (P\<0.05) ([Table II](#tII-etm-0-0-4327){ref-type="table"}).

Discussion
==========

Heterotopic ossification has similar histological and imaging features as normal bone ([@b8-etm-0-0-4327]). Backbone is smooth, irregular in shape, benign tumor-like mature bone, extending to normal bone surface and not invading bone cortex. Bone metabolic activity of heterotopic ossification is high. Bone mineralization rate, suture width and osteoblast and osteoclast number increase significantly, and it has stronger rate of mineralization during the early stage of proliferation and differentiation ([@b9-etm-0-0-4327]).

Treatment of heterotopic ossification is based on severity, range and joint function disturbance ([@b10-etm-0-0-4327]). It includes medi-cation, radiation and surgical intervention ([@b11-etm-0-0-4327]). Non-steroidal anti-inflammatory medications and diphosphates are the main drugs used in the treatment of the heterotopic ossification ([@b12-etm-0-0-4327]). There are a few disadvantages associated with these drugs. These include serious side effects and hemorrhage in digestive tract ([@b13-etm-0-0-4327]). Ossification may continue once medications are interrupted ([@b14-etm-0-0-4327]). Beside its carcinogenic risk, radiotherapy cannot reduce the mature heterotopic bone volume ([@b15-etm-0-0-4327]).

We built a rabbit-human artificial joint aseptic loosening model successfully, and discovered that alendronate sodium bone cement local load system effectively prevented periprosthetic osteolysis and bone absorption mediated by titanium particles. It also improved periprosthetic bone mineral density, increase prosthesis, bone interface shear strength and periprosthetic bone mass fraction ([@b16-etm-0-0-4327]). We locally applied high molecular polyethylene particles in heterotopic ossification model, and discovered that heterotopic ossification incidence in the observation group was significantly lower than that in the control group.

BMP-2, TGF-β, IL-1, TNF-α, Runx2 and MMP-9 levels in observation group were significantly lower than those in the control group. BMP-2 is an osteogenic induction factor, which can facilitate osteoblastic differentiation and regulate the occurrence of heterotopic ossification. BMP-2 expression level was shown to be related to bone formation level ([@b17-etm-0-0-4327]). TGF-β regulates cells proliferation and differentiation, increases the synthesis of extracellular matrix and facilitates cartilage tissue collagen synthesis ([@b18-etm-0-0-4327]). BMP-2 affects the occurrence of entochondrostosis under the regulation of TGF-β. Inflammatory cytokines such as IL-1 and TNF-α, produced by post-trauma tissue, can stimulate the expression of BMP-2, increase proliferation and differentiation of mesenchymal stem cells in muscular tissue and increase bone formation ([@b19-etm-0-0-4327]). Runx2 is an osteoblast specific transcription factor, which directly regulates type I collagen and osteocalcin bone gene expression and participates in ECM signal path activation process of osteogenic precursor cells ([@b20-etm-0-0-4327]). MMP-9 is a saccharifying protease, which is secreted by interstitial cells, and participates in nuclear migration of endothelial cells, epithelial cells, fibroblast and keratinocytes. It is an important indicator for early extracellular matrix recombination ([@b21-etm-0-0-4327]). MMP-9 regulates and degrades various types of extracellular matrix, and can activate other types of MMP protein and trigger an inflammatory cascade. MMP-9 participates in bone remodeling and angiogenesis process, which can be regarded as biomarker with higher sensitivity and specificity in neurological heterotopic ossification ([@b22-etm-0-0-4327]).

We concluded that, high molecular polyethylene particles had a significant inhibiting effect on local heterotopic ossification. This may be related to the release of local inflammatory factors.
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###### 

Histological examination comparison.

  Category                 Control group   Observation group   t-test   P-value
  ------------------------ --------------- ------------------- -------- ---------
  Trabecular bone volume                                                
      4th week             2.2±0.5         3.6±0.8             5.632    0.024
      8th week             2.3±0.6         4.5±1.1             6.432    0.016
    12th week              2.4±0.6         5.3±1.5             7.412    0.009
  Thickness                                                             
      4th week             1.5±0.4         1.9±0.6             4.236    0.032
      8th week             1.6±0.5         2.2±0.8             4.958    0.025
    12th week              1.7±0.6         2.6±1.2             5.237    0.021
  Quantity                                                              
      4th week             2.4±0.9         3.0±0.9             4.526    0.030
      8th week             2.3±0.8         3.5±1.3             5.714    0.022
    12th week              2.4±1.0         3.9±1.5             6.326    0.017

###### 

Inflammatory factor expression quantity comparison.

  Category       Control group   Observation group   t-test   P-value
  -------------- --------------- ------------------- -------- ---------
  BMP-2                                                       
      4th week     5.6±1.2       2.3±0.6             5.236    0.032
      8th week     9.4±1.8       5.4±0.9             6.421    0.025
    12th week    11.5±2.2        7.6±1.2             7.523    0.014
  TGF-β                                                       
      4th week     3.6±0.8       1.2±0.4             5.629    0.029
      8th week     7.2±1.3       2.3±0.9             6.532    0.023
    12th week      9.5±1.9       4.6±1.3             7.524    0.015
  IL-1                                                        
      4th week     4.5±1.1       2.1±0.7             5.236    0.033
      8th week     6.8±1.9       3.3±1.1             5.895    0.026
    12th week      8.4±2.2       5.2±1.6             6.632    0.023
  TNF-α                                                       
      4th week     5.6±1.3       2.4±0.6             5.426    0.030
      8th week     9.4±1.8       4.3±1.2             6.329    0.026
    12th week    11.7±2.4        6.6±1.7             7.521    0.015
  Runx2                                                       
      4th week     3.3±0.6       1.2±0.3             4.629    0.038
      8th week     7.2±1.4       2.3±0.8             5.638    0.030
    12th week      9.5±2.3       3.4±1.5             6.429    0.024
  MMP-9                                                       
      4th week     6.2±1.3       3.2±1.1             5.826    0.032
      8th week     9.5±2.4       4.5±1.8             6.754    0.025
    12th week    11.9±3.2        6.7±2.4             7.895    0.013

BMP-2, bone morphogenetic protein 2; TGF-β, transforming growth factor-β; IL-1, interleukin-1; TNF-α, tumor necrosis factor-α; Runx2, runt-related transcription factor 2; MMP-9, matrix metalloproteinase-9.
